Study of X0002 Following Escalating Single and Multiple Doses Administered as Topical Application in Healthy Volunteers

NCT02794740 | Completed Phase 1

• 1 other identifier: TFR-X0002-101
• Study Type: interventional
• Target: 34
• Locations: 1 country
• Sites: 1

Brief Summary

Primary Objectives: To evaluate the safety and tolerability of escalating single and multiple doses of X0002 administered as a topical application. Secondary Objectives: To characterize the single and and multiple pharmacokinetics of escalating doses of X0002 and its active metabolite ibuprofen as a topical application.

Conditions

Osteoarthritis

Keywords

Osteoarthritis

Outcome Measures

Primary Outcomes (1)

• Incidence of adverse events

  Adverse Event; Vital Signs; Physical Examination; Laboratory Examination; Electrocardiograph; Skin Irritation

  Single Dose Arms:6days;Multiple Doses Arms:17days

Secondary Outcomes (1)

• Pharmacokinetic parameters(Maximum Plasma Concentration [Cmax])

  Single Dose Arms:0-120hours;Multiple Doses Arms:0-120hours post-dose;11th day pre-dose;12th day 0-120 hours post-dose.

Other Outcomes (1)

• Pharmacokinetic parameters(Area Under Curve [AUC])

  Single Dose Arms:0-120hours;Multiple Doses Arms:0-120hours post-dose;11th day pre-dose;12th day 0-120 hours post-dose.

Study Arms (7)

X0002 First Dose

EXPERIMENTAL

Preliminary Experiment,4 Subjects,Single-Dose,Once,Non-Blind.

Drug: X0002

X0002 Second Dose

EXPERIMENTAL

8 Subjects,Single Dose once and Multiple Doses 7 Days,b.i.d,12 Hours Apart,Double-Blind.

Drug: X0002

Placebo Second Dose

PLACEBO COMPARATOR

2 Subjects,Single Dose once and Multiple Doses 7 Days,b.i.d,12 Hours Apart,Double-Blind.

Drug: Placebo

X0002 Third Dose

EXPERIMENTAL

8 Subjects,Single Dose once and Multiple Doses 7 Days,b.i.d,12 Hours Apart,Double-Blind.

Drug: X0002

Placebo Third Dose

PLACEBO COMPARATOR

2 Subjects,Single Dose once and Multiple Doses 7 Days,b.i.d,12 Hours Apart,Double-Blind.

Drug: Placebo

X0002 Fourth Dose

EXPERIMENTAL

8 Subjects,Single Dose,Once,Double-Blind.

Drug: X0002

Placebo Fourth Dose

PLACEBO COMPARATOR

2 Subjects,Single Dose,Once,Double-Blind.

Drug: Placebo

Interventions

X0002 DRUG

External Spray

X0002 First Dose; X0002 Fourth Dose; X0002 Second Dose; X0002 Third Dose

Placebo DRUG

External Spray

Placebo Fourth Dose; Placebo Second Dose; Placebo Third Dose

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Gender: male or female, each sex ratio does no less 1/3;
• Were between the ages of 18 and 45 years, inclusive. General condition is will;
• Were between the Body Mass Index (BMI) of 19-28, inclusive; BMI=Weight(kg)/Height2 (m2); Weight≥50kg (female) and 60kg (male);
• Nearly half of the year, no child care program and agree to take effective measures to contraception during the study period, blood pregnancy test of women in childbearing age was negative;
• Vital signs (measurement seated after resting 5 minutes) in the following range
• Temperature (auxiliary temperature): 35.0-37.0℃
• Systolic Pressure: 90-139mmHg
• Diastolic Pressure: 60-89mmHg
• sphygmus: 55-99bpm
• Subjects to fully understand the purpose, properties, method and reactions may occur of test drug trials. Were capable of giving informed consents voluntarily, and agreed to comply with the requirements of clinical protocols.

You may not qualify if:

• Primary disease in important organs;
• Mental or physical disability;
• Familial hereditary diseases;
• Clinically significant history of Electrocardiograph (ECG) abnormality, or Electrocardiograph (ECG) abnormality in the Screening or Baseline;
• Clinically significant abnormities in laboratory examination:
• Clinically significant abnormities in Liver Function Tests, for example aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP) or bilirubin.
• Creatinine and Urea Nitrogen exceeded the upper limit of normal, or significant abnormities in urinary composition.
• Clinically significant abnormities of routine blood test, for example anemia, Leukocyte reduced, Platelet significantly reduced,etc.( Combined with adverse events in the laboratory to determine the value of abnormal).
• Abnormality of immunology, including HIV(human immunodeficiency virus) antibody positive, Hepatitis B surface antigen (HBsAg) positive, HCV(hepatitis C virus) antibody positive or Syphilis antibody positive.
• Drug abusers,or drug screening positive;
• Who was addicted to alcohol and tobacco (drinking 14 units of alcohol per week: 1 unit = beer 285 ml, or liquor 25 ml, or wine 1 cup. numbers of daily smoking ≥ 5) and / or not smoking and drinking in the test period;Test positive for nicotine or breath test positive for alcohol(\>0.0mg/100ml);
• Took any drug long excretory phase that may affect the study, or in the past 3 months participated in any drug clinical trials;
• Entering the group 4 weeks ago used any prescription drugs ,or used any over the counter (OTC) drugs within 2 weeks (vitamins, herbal tonics, etc.), or before entering the group within 2 weeks took excessively food that effected drug metabolizing enzymes, such as grapefruit or grapefruit drink. Can the use of acetaminophen, but must record report in case report form (CRF）;
• A history of gastrointestinal bleeding or peptic ulcers, drugs allergy for aspirin or hypersensitivity to aspirin or other NSAIDs (Non-Steroidal Antiinflammatory Drugs), or a history of asthma or other allergic-type reactions after taking aspirin or other NSAIDs(Non-Steroidal Antiinflammatory Drugs); A history of intolerance or hypersensitivity to ibuprofenamine hydrochloride or any excipients or to the diluent ethanol;
• Donation or blood collection, or acute loss of blood during the 3 months prior to screening( more than 400ml);

Sponsors & Collaborators

• Tianjin XinChen-Techfields Pharma Co., LTD.: lead

Study Sites (1)

Tianjin Xinchen-Techfields Pharma Co. Ltd

Tianjin, Tianjin Municipality, 300000, China

Location

MeSH Terms

Conditions

Osteoarthritis

Condition Hierarchy (Ancestors)

Arthritis; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 1, 2016
• First Posted: June 9, 2016
• Study Start: June 1, 2016
• Primary Completion: March 1, 2017
• Study Completion: March 29, 2017
• Last Updated: September 12, 2018

Record last verified: 2018-09

Locations

CN (1)